New evidence suggests that mesothelioma patients whose tumors express two particular proteins do not live as long as other mesothelioma patients. An international team of scientists including mesothelioma researchers at the National Cancer Institute say ALCAM (also called CD166) and PD-L1 (CD274) are both associated with “significantly decreased” survival in pleural mesothelioma. Understanding ALCAM and PD-L1 ALCAM is a type I transmembrane protein that regulates … Continue reading These Proteins Appear to Shorten Mesothelioma Survival
A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing DETERMINE trial which suggests that the survival rates are roughly the same for previously-treated mesothelioma patients whether they later received treatment with tremelimumab or a placebo. What is Tremelimumab? … Continue reading Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival
Australian scientists say it may be possible to artificially reduce the levels of a protein that helps mesothelioma tumors hide from the immune system. The new research published in the Journal of Thoracic Oncology could open the door to more effective immunotherapy treatments for pleural mesothelioma. The Importance of PD-L1 Expression A cell surface protein called PD-L1 is key to the effectiveness of several new … Continue reading MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma
Viruses may soon be playing a bigger role in the fight against malignant mesothelioma and other thoracic cancers. A pair of biologists from Minnesota say there is evidence that, in addition to killing mesothelioma cells directly, specific kinds of altered viruses might help make mesothelioma immunotherapy treatment more effective. How Does Immunotherapy Work? Like many other types of cancer, mesothelioma tumors are able to grow unchecked … Continue reading Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma
New research suggests that, in the battle against malignant pleural mesothelioma, a treatment combining of immunotherapy drugs with radiotherapy may be a powerful new weapon. Researchers at the University of Pennsylvania reached that conclusion after reviewing the few existing studies on this emerging multimodal mesothelioma treatment for an article in Translational Lung Cancer Research. Current available treatments for pleural mesothelioma, an aggressive lung-related cancer, include surgical resection, … Continue reading Immunotherapy and Radiation: A Powerful Mesothelioma Combo
Preliminary tests of a potential new mesothelioma treatment have yielded some exciting results at the University of Hawaii Cancer Center. Mesothelioma researchers there are evaluating an immune system modulator called FTY720 or fingolimod. Derived from a fungus called Iscaria sinclairii, FTY720 has been used to treat the relapsing form of multiple sclerosis. Although FTY720 has shown what the research team calls “therapeutic potential” in some … Continue reading MS Drug May Help Treat Malignant Mesothelioma, Too
Researchers with a biotechnology company that makes antibody-drug conjugates (ADC) for hard-to-treat cancers like malignant mesothelioma say careful patient selection is the key to treatment success. Writing in the journal Advances in Therapy, John Lambert and Charles Morris of Massachusetts-based ImmunoGen call for the development of a “patient selection strategy” so that more mesothelioma patients and those with other cancers can take advantage of the … Continue reading The Key to Mesothelioma Treatment Success with Immunotherapy
There is new evidence that a mesothelioma patient’s nutritional status could have an impact on their treatment outcomes. A group of Japanese surgeons, oncologists and pathologists compared the treatment responses of 83 patients with pleural mesothelioma and found that patients with the poorest nutritional status tended to have the poorest mesothelioma prognosis. Controlling Nutritional Status Score To reach their conclusion, the researchers used a tool … Continue reading The Impact of Nutritional Status on Mesothelioma Survival
Immunotherapy is an important emerging therapeutic strategy for several types of cancer, but the jury is still out on whether it will eventually be a viable approach for malignant pleural mesothelioma. In a newly-published special report on the immune checkpoint inhibitor tremelimumab, researchers at the University of Salford in the UK call the use of such drugs “largely questionable” for pleural mesothelioma treatment. Their concerns, … Continue reading Immunotherapy for Pleural Mesothelioma: Does it Work?
There may be new hope for malignant mesothelioma patients whose cancer recurs after treatment. A presentation at the recent World Lung Cancer conference in Vienna earlier this month suggests that the immunotherapy drug nivolumab (brand name Opdivo) could help people with pleural mesothelioma who have run out of treatment options. The author of the new study says his Amsterdam-based team has recorded mesothelioma survival of … Continue reading Immunotherapy Drug May Be New Option for Recurrent Mesothelioma
Get your free copy of
“Surviving Mesothelioma” Today!